On the contrary, there seems to be an increased risk of ER+ tumors, increased incidence of triple-negative breast cancers (TNBC), and worse overall survival in HER2+ carriers regarding postmenopausal patients living with obesity who develop breast cancer 28. Here, ESR1 is linked to obesity due to melanocortin 4 receptor deficiency.